Marshall Wace’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Marshall Wace’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-117,688	Closed	-$718K	–	4551
2021 Q3	$718K	Buy	+117,688	New	+$734K	﹤0.01%	2211
2021 Q2	–	Sell	-124,512	Closed	-$1.11M	–	3449
2021 Q1	$1.11M	Buy	+124,512	New	+$1.43M	0.01%	1604
2020 Q4	–	Sell	-39,330	Closed	-$409K	–	2332
2020 Q3	$409K	Sell	39,330 -129,203	-77%	-$1.58M	﹤0.01%	1286
2020 Q2	$2.21M	Buy	+168,533	New	+$1.75M	0.02%	754
2019 Q1	–	Sell	-3,320	Closed	-$38K	–	2183
2018 Q4	$38K	Buy	+3,320	New	+$52.1K	﹤0.01%	1482
2015 Q4	–	Sell	-132,945	Closed	-$1.98M	–	1180
2015 Q3	$1.98M	Buy	+132,945	New	+$3.12M	0.02%	461

Marshall Wace's FLXN Position: Q4 2021 in Review

Marshall Wace sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 117,688 shares — an estimated $718K sold.

Marshall Wace first reported a position in FLXN in Q3 2015 and held it in 6 quarters. The position peaked at $2.21M in Q2 2020. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.

Marshall Wace reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Marshall Wace sold 117,688 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $718K.
Marshall Wace first reported a position in Flexion Therapeutics, Inc. in Q3 2015 and held it in 6 quarters.
Marshall Wace's Flexion Therapeutics, Inc. position peaked at $2.21M in Q2 2020.
1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.